VX 745

Key Product Details

Product Description

VX 745 is a highly potent and selective p38α/MAPK14 inhibitor, also inhibits p38β (IC₅₀ values are 10 nM and 220 nM respectively). VX 745 blocks TNFα production in LPS-stimulated HWB in vitro (IC₅₀ = 51-180 nM). Also reduces phosphorylation of p38MAPKα and the downstream target Hsp27, leading to vasodilation, reduces IL-1β levels and amyloid plaques in cortex and hippocampus and lowers CSF tau levels in vivo.

External Portal Information

Chemicalprobes.org

is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of VX 745 is reviewed on the chemical probes website.

Product Specifications for VX 745

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for VX 745

The following data is based on the product molecular weight 436.26.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.29 mL	11.46 mL	22.92 mL
5 mM	0.46 mL	2.29 mL	4.58 mL
10 mM	0.23 mL	1.15 mL	2.29 mL
50 mM	0.05 mL	0.23 mL	0.46 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 21 publications citing the usage of this product.

• Alam Selective brain-targeted antagonism of p38 MAPKα reduces hippocampal IL-1 levels and improves Morris Water Maze performance in aged rats. J.Alzheimers Dis. 2015 PMID: 26401942
• Petrova p38 MAPK signalling regulates cytokine production in IL-33 stimulated type 2 innate lymphoid cells. Sci.Rep. 2020 PMID: 32103032
• Pandey Neflamapimod induces vasodilation in resistance mesenteric arteries by inhibiting p38 MAPKα and downstream Hsp27 phosphorylation. Sci.Rep. 2022 PMID: 35318382
• Duffy The discovery of VX-745: a novel and selective p38α kinase inhibitor. ACS Med.Chem.Lett. 2011 PMID: 24900264
• Goldstein Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J.Med.Chem. 2010 PMID: 19950901
• Bagley Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Bioorg.Med.Chem.Lett. 2007 PMID: 17659871

Product Documents for VX 745